159 related articles for article (PubMed ID: 12430878)
1. Novel biologically based therapies for multiple myeloma.
Munshi NC; Hideshima T; Chauhan D; Richardson P; Anderson KC
Int J Hematol; 2002 Aug; 76 Suppl 1():340-1. PubMed ID: 12430878
[No Abstract] [Full Text] [Related]
2. Novel therapies for multiple myeloma.
Hayashi T; Hideshima T; Anderson KC
Br J Haematol; 2003 Jan; 120(1):10-7. PubMed ID: 12492571
[No Abstract] [Full Text] [Related]
3. Novel therapies for multiple myeloma.
Ryoo JJ; Cole CE; Anderson KC
Blood Rev; 2002 Sep; 16(3):167-74. PubMed ID: 12163002
[TBL] [Abstract][Full Text] [Related]
4. Co-biomodulation with arsenic trioxide in multiple myeloma.
Gallagher RE
Leuk Res; 2001 Mar; 25(3):237-9. PubMed ID: 11226520
[No Abstract] [Full Text] [Related]
5. Nontraditional cytotoxic therapies for relapsed/refractory multiple myeloma.
Hussein MA
Oncologist; 2002; 7 Suppl 1():20-9. PubMed ID: 11961206
[TBL] [Abstract][Full Text] [Related]
6. Understanding novel therapeutic agents for multiple myeloma.
Tariman JD
Clin J Oncol Nurs; 2003; 7(5):521-8. PubMed ID: 14603548
[TBL] [Abstract][Full Text] [Related]
7. Arsenic trioxide in multiple myeloma: rationale and future directions.
Anderson KC; Boise LH; Louie R; Waxman S
Cancer J; 2002; 8(1):12-25. PubMed ID: 11895198
[TBL] [Abstract][Full Text] [Related]
8. Arsenic trioxide: an emerging therapy for multiple myeloma.
Munshi NC
Oncologist; 2001; 6 Suppl 2():17-21. PubMed ID: 11331436
[TBL] [Abstract][Full Text] [Related]
9. The emerging role of arsenic trioxide as an immunomodulatory agent in the management of multiple myeloma.
Kalmadi SR; Hussein MA
Acta Haematol; 2006; 116(1):1-7. PubMed ID: 16809883
[TBL] [Abstract][Full Text] [Related]
10. Multiple myeloma: present and future.
Hussein MA; Juturi JV; Lieberman I
Curr Opin Oncol; 2002 Jan; 14(1):31-5. PubMed ID: 11790977
[TBL] [Abstract][Full Text] [Related]
11. Arsenic trioxide: expanding roles for an ancient drug?
Ravandi F
Leukemia; 2004 Sep; 18(9):1457-9. PubMed ID: 15269784
[No Abstract] [Full Text] [Related]
12. Targeted therapy in multiple myeloma.
Chng WJ; Lau LG; Yusof N; Mow BM
Cancer Control; 2005 Apr; 12(2):91-104. PubMed ID: 15855892
[TBL] [Abstract][Full Text] [Related]
13. Clinical trials referral resource. Clinical trials with arsenic trioxide.
Murgo AJ; McBee WL; Cheson BD
Oncology (Williston Park); 2000 Feb; 14(2):206, 211, 215-6 passim. PubMed ID: 10736809
[No Abstract] [Full Text] [Related]
14. Targeting the mitochondria: an exciting new approach to myeloma therapy. Commentary re: N. J. Bahlis et al., Feasibility and correlates of arsenic trioxide combined with ascorbic acid-mediated depletion of intracellular glutathione for the treatment of relapsed/refractory multiple myeloma. Clin. Cancer Res., 8: 3658-3668, 2002.
Dalton WS
Clin Cancer Res; 2002 Dec; 8(12):3643-5. PubMed ID: 12473572
[No Abstract] [Full Text] [Related]
15. [Pharmacological and clinical properties of arsenic trioxide (Trisenox) for relapse or refractory acute promyelocytic leukemia therapy].
Tajima M
Nihon Yakurigaku Zasshi; 2005 Jun; 125(6):389-96. PubMed ID: 16079563
[No Abstract] [Full Text] [Related]
16. [The plasma cell myeloma--molecular pathogenesis and target therapies].
Hess U
Ther Umsch; 2006 Apr; 63(4):233-6. PubMed ID: 16689452
[TBL] [Abstract][Full Text] [Related]
17. [Progression of foundational and clinical studies on use of arsenic trioxide in treatment of lymphoma--review].
Li LH; Li HM
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2007 Dec; 15(6):1335-9. PubMed ID: 18088496
[TBL] [Abstract][Full Text] [Related]
18. Clinical activity of arsenic trioxide for the treatment of multiple myeloma.
Munshi NC; Tricot G; Desikan R; Badros A; Zangari M; Toor A; Morris C; Anaissie E; Barlogie B
Leukemia; 2002 Sep; 16(9):1835-7. PubMed ID: 12200700
[TBL] [Abstract][Full Text] [Related]
19. Anti-leukemic and anti-angiogenesis efficacy of arsenic trioxide in new cases of acute promyelocytic leukemia.
Alimoghaddam K; Shariftabrizi A; Tavangar SM; Sanaat Z; Rostami S; Jahani M; Ghavamzadeh A
Leuk Lymphoma; 2006 Jan; 47(1):81-8. PubMed ID: 16321832
[TBL] [Abstract][Full Text] [Related]
20. Phase 2 study of arsenic trioxide in patients with relapsed or refractory multiple myeloma.
Hussein MA; Saleh M; Ravandi F; Mason J; Rifkin RM; Ellison R
Br J Haematol; 2004 May; 125(4):470-6. PubMed ID: 15142117
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]